ATE357236T1 - Verwendung von dem quinazolin derivat zd6474 kombiniert mit gemcitabin und gegebenenfalls ionisierender strahlung für die behandlung von krebs - Google Patents

Verwendung von dem quinazolin derivat zd6474 kombiniert mit gemcitabin und gegebenenfalls ionisierender strahlung für die behandlung von krebs

Info

Publication number
ATE357236T1
ATE357236T1 AT03751032T AT03751032T ATE357236T1 AT E357236 T1 ATE357236 T1 AT E357236T1 AT 03751032 T AT03751032 T AT 03751032T AT 03751032 T AT03751032 T AT 03751032T AT E357236 T1 ATE357236 T1 AT E357236T1
Authority
AT
Austria
Prior art keywords
gemcitabine
treatment
cancer
appropriate
combined
Prior art date
Application number
AT03751032T
Other languages
English (en)
Inventor
Alan Barge
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of ATE357236T1 publication Critical patent/ATE357236T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Iron Core Of Rotating Electric Machines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT03751032T 2002-10-09 2003-10-06 Verwendung von dem quinazolin derivat zd6474 kombiniert mit gemcitabin und gegebenenfalls ionisierender strahlung für die behandlung von krebs ATE357236T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0223380.7A GB0223380D0 (en) 2002-10-09 2002-10-09 Combination therapy

Publications (1)

Publication Number Publication Date
ATE357236T1 true ATE357236T1 (de) 2007-04-15

Family

ID=9945538

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03751032T ATE357236T1 (de) 2002-10-09 2003-10-06 Verwendung von dem quinazolin derivat zd6474 kombiniert mit gemcitabin und gegebenenfalls ionisierender strahlung für die behandlung von krebs

Country Status (22)

Country Link
US (2) US20060009418A1 (de)
EP (1) EP1551409B1 (de)
JP (2) JP5416328B2 (de)
KR (1) KR101098061B1 (de)
CN (1) CN100363004C (de)
AT (1) ATE357236T1 (de)
AU (1) AU2003269253B2 (de)
BR (1) BR0315088A (de)
CA (1) CA2501651C (de)
CY (1) CY1106601T1 (de)
DE (1) DE60312715T2 (de)
DK (1) DK1551409T3 (de)
ES (1) ES2282656T3 (de)
GB (1) GB0223380D0 (de)
IL (1) IL167633A (de)
MX (1) MXPA05003595A (de)
NO (1) NO330601B1 (de)
NZ (1) NZ538999A (de)
PT (1) PT1551409E (de)
SI (1) SI1551409T1 (de)
WO (1) WO2004032937A1 (de)
ZA (1) ZA200502753B (de)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL149034A0 (en) 1999-11-05 2002-11-10 Astrazeneca Ab Quinazoline derivatives as vegf inhibitors
GB0008269D0 (en) 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy
SI1274692T1 (sl) 2000-04-07 2006-12-31 Astrazeneca Ab Kinazolinske spojine
EP1506962B1 (de) 2000-10-20 2008-07-02 Eisai R&D Management Co., Ltd. Stickstoff enthaltende aromatische Heterozyklen
GB0126879D0 (en) * 2001-11-08 2002-01-02 Astrazeneca Ab Combination therapy
CN1625555A (zh) 2002-02-01 2005-06-08 阿斯特拉曾尼卡有限公司 喹唑啉化合物
GB0218526D0 (en) * 2002-08-09 2002-09-18 Astrazeneca Ab Combination therapy
GB0223380D0 (en) * 2002-10-09 2002-11-13 Astrazeneca Ab Combination therapy
NZ539408A (en) 2002-11-04 2007-09-28 Astrazeneca Ab Quinazoline derivatives as SRC tyrosine kinase inhibitors for treating solid tumours
ATE506062T1 (de) * 2003-02-13 2011-05-15 Astrazeneca Ab Kombinationstherapie von zd6474 mit 5-fu oder/und cpt-11
JPWO2004080462A1 (ja) 2003-03-10 2006-06-08 エーザイ株式会社 ｃ−Ｋｉｔキナーゼ阻害剤
GB0310401D0 (en) * 2003-05-07 2003-06-11 Astrazeneca Ab Therapeutic agent
WO2005004870A1 (en) * 2003-07-10 2005-01-20 Astrazeneca Ab Use of the quinazoline derivative zd6474 combined with platinum compounds and optionally ionising radiation in the treatment of diseases associated with angiogenesis and/or increased vascular permeability
JP4303726B2 (ja) 2003-11-11 2009-07-29 エーザイ・アール・アンド・ディー・マネジメント株式会社 ウレア誘導体およびその製造方法
US8969379B2 (en) 2004-09-17 2015-03-03 Eisai R&D Management Co., Ltd. Pharmaceutical compositions of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7=methoxy-6-quinolinecarboxide
EP1804802A2 (de) * 2004-09-27 2007-07-11 AstraZeneca AB Kombination aus zd6474 und imatinib
GB0424339D0 (en) * 2004-11-03 2004-12-08 Astrazeneca Ab Combination therapy
EP1901754A2 (de) * 2005-07-06 2008-03-26 AstraZeneca AB Kombinationstherapie gegen krebs mit azd2171 und gemcitabin
US20080219977A1 (en) * 2005-07-27 2008-09-11 Isaiah Josh Fidler Combinations Comprising Gemcitabine and Tyrosine Kinase Inhibitors for the Treatment of Pancreatic Cancer
WO2007015578A1 (ja) 2005-08-02 2007-02-08 Eisai R & D Management Co., Ltd. 血管新生阻害物質の効果を検定する方法
GB0519879D0 (en) 2005-09-30 2005-11-09 Astrazeneca Ab Chemical process
EP1971338B8 (de) * 2005-12-22 2011-09-21 AstraZeneca AB Kombination von zd6474 und pemetrexed
CA2652442C (en) 2006-05-18 2014-12-09 Eisai R & D Management Co., Ltd. Antitumor agent for thyroid cancer
EP2065372B1 (de) 2006-08-28 2012-11-28 Eisai R&D Management Co., Ltd. Antitumormittel gegen undifferenzierten magenkrebs
WO2008037996A1 (en) * 2006-09-29 2008-04-03 Astrazeneca Ab Combination of zd6474 and bevacizumab for cancer therapy
WO2008088088A1 (ja) 2007-01-19 2008-07-24 Eisai R & D Management Co., Ltd. 膵癌治療用組成物
US8962655B2 (en) 2007-01-29 2015-02-24 Eisai R&D Management Co., Ltd. Composition for treatment of undifferentiated gastric cancer
CN101848895B (zh) 2007-11-09 2013-10-23 卫材R&D管理有限公司 血管新生抑制物质和抗肿瘤性铂络合物的组合使用
US20120070368A1 (en) * 2010-04-16 2012-03-22 Exelixis, Inc. Methods of Using C-Met Modulators
ES2573515T3 (es) 2010-06-25 2016-06-08 Eisai R&D Management Co., Ltd. Agente antitumoral que emplea compuestos con efecto inhibitorio de cinasas combinados
MX2013009931A (es) 2011-04-18 2013-10-01 Eisai R&D Man Co Ltd Agentes terapeuticos contra tumores.
EP2714937B1 (de) 2011-06-03 2018-11-14 Eisai R&D Management Co., Ltd. Biomarker zur vorhersage und beurteilung des ansprechens von schilddrüsen- und nierenkrebspatienten auf lenvatinibverbindungen
MX2015004979A (es) 2012-12-21 2015-07-17 Eisai R&D Man Co Ltd Forma amorfa de derivado de quinolina y metodo para su produccion.
NZ714049A (en) 2013-05-14 2020-05-29 Eisai R&D Man Co Ltd Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
CN113683564A (zh) 2014-08-28 2021-11-23 卫材R&D管理有限公司 高纯度喹啉衍生物及其生产方法
LT3263106T (lt) 2015-02-25 2024-01-10 Eisai R&D Management Co., Ltd. Chinolino darinių kartumo sumažinimo būdas
CA2978226C (en) 2015-03-04 2025-02-18 Eisai R&D Management Co., Ltd. COMBINATION OF A PD-1 ANTAGONIST AND A VEGFR/FGFR/RET TYROSINE KINASE INHIBITOR TO TREAT CANCER
CN107801379B (zh) 2015-06-16 2021-05-25 卫材R&D管理有限公司 抗癌剂
RU2718048C2 (ru) 2015-08-20 2020-03-30 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Противоопухолевое терапевтическое средство
CN106619688A (zh) * 2016-12-27 2017-05-10 郑州郑先医药科技有限公司 一种治疗糖尿病的药物组合物及应用
CN106727657A (zh) * 2016-12-27 2017-05-31 郑州郑先医药科技有限公司 一种治疗糖尿病的西药组合物及应用
WO2018147275A1 (ja) 2017-02-08 2018-08-16 エーザイ・アール・アンド・ディー・マネジメント株式会社 腫瘍治療用医薬組成物
RU2019134940A (ru) 2017-05-16 2021-06-16 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Лечение гепатоцеллюлярной карциномы

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0184365B1 (de) * 1984-12-04 1993-08-04 Eli Lilly And Company Tumorbehandlung bei Säugetieren
US7132458B2 (en) * 1994-08-10 2006-11-07 Chemaphor Inc. Oxidized carotenoid fractions and ketoaldehyde useful as cell-differentiation inducers, cytostatic agents, and anti-tumor agents
GB9718972D0 (en) * 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
IL149034A0 (en) * 1999-11-05 2002-11-10 Astrazeneca Ab Quinazoline derivatives as vegf inhibitors
TWI310684B (en) * 2000-03-27 2009-06-11 Bristol Myers Squibb Co Synergistic pharmaceutical kits for treating cancer
GB0008269D0 (en) * 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy
US6953679B2 (en) * 2000-09-19 2005-10-11 Bristol-Myers Squibb Company Method for the preparation of fused heterocyclic succinimide compounds and analogs thereof
GB0126879D0 (en) * 2001-11-08 2002-01-02 Astrazeneca Ab Combination therapy
GB0218526D0 (en) * 2002-08-09 2002-09-18 Astrazeneca Ab Combination therapy
EP1534287A1 (de) * 2002-08-09 2005-06-01 Astrazeneca AB Kombination von zd6474, einem inhibitor des vaskulären endothelialen wachstumsfaktorrezeptors, mit radiotherapie für die behandlung von krebs
GB0223380D0 (en) * 2002-10-09 2002-11-13 Astrazeneca Ab Combination therapy
GB0226434D0 (en) * 2002-11-13 2002-12-18 Astrazeneca Ab Combination product
ATE506062T1 (de) * 2003-02-13 2011-05-15 Astrazeneca Ab Kombinationstherapie von zd6474 mit 5-fu oder/und cpt-11
WO2005004870A1 (en) * 2003-07-10 2005-01-20 Astrazeneca Ab Use of the quinazoline derivative zd6474 combined with platinum compounds and optionally ionising radiation in the treatment of diseases associated with angiogenesis and/or increased vascular permeability
EP1804802A2 (de) * 2004-09-27 2007-07-11 AstraZeneca AB Kombination aus zd6474 und imatinib
GB0424339D0 (en) * 2004-11-03 2004-12-08 Astrazeneca Ab Combination therapy
EP1901754A2 (de) * 2005-07-06 2008-03-26 AstraZeneca AB Kombinationstherapie gegen krebs mit azd2171 und gemcitabin
EP1971338B8 (de) * 2005-12-22 2011-09-21 AstraZeneca AB Kombination von zd6474 und pemetrexed
WO2008037996A1 (en) * 2006-09-29 2008-04-03 Astrazeneca Ab Combination of zd6474 and bevacizumab for cancer therapy
US20100212978A1 (en) * 2009-02-23 2010-08-26 Wen-Hung Huang Bicycle with two operation molds

Also Published As

Publication number Publication date
CN1703223A (zh) 2005-11-30
IL167633A (en) 2013-03-24
DK1551409T3 (da) 2007-06-11
US20060009418A1 (en) 2006-01-12
EP1551409A1 (de) 2005-07-13
ZA200502753B (en) 2006-03-29
ES2282656T3 (es) 2007-10-16
NO330601B1 (no) 2011-05-23
CN100363004C (zh) 2008-01-23
JP5416328B2 (ja) 2014-02-12
WO2004032937A1 (en) 2004-04-22
DE60312715D1 (de) 2007-05-03
AU2003269253B2 (en) 2007-04-05
CA2501651A1 (en) 2004-04-22
US20100120708A1 (en) 2010-05-13
JP2006504723A (ja) 2006-02-09
SI1551409T1 (sl) 2007-08-31
CY1106601T1 (el) 2012-01-25
AU2003269253A1 (en) 2004-05-04
NO20051575L (no) 2005-04-25
NZ538999A (en) 2008-02-29
PT1551409E (pt) 2007-05-31
CA2501651C (en) 2011-02-15
HK1078771A1 (en) 2006-03-24
JP2011088921A (ja) 2011-05-06
KR101098061B1 (ko) 2011-12-26
MXPA05003595A (es) 2005-06-03
KR20050055070A (ko) 2005-06-10
GB0223380D0 (en) 2002-11-13
BR0315088A (pt) 2005-08-16
EP1551409B1 (de) 2007-03-21
DE60312715T2 (de) 2007-12-06

Similar Documents

Publication Publication Date Title
ATE357236T1 (de) Verwendung von dem quinazolin derivat zd6474 kombiniert mit gemcitabin und gegebenenfalls ionisierender strahlung für die behandlung von krebs
ATE478671T1 (de) Verwendung des chinazolin-derivats zd6474 in kombination mit platinverbindungen und optional ionisierender strahlung bei der behandlung von erkrankungen im zusammenhang mit angiogenese und/oder erhöhter gefässpermeabilität
NO20082567L (no) Kombinasjon av ZD6474 og pemetrexed
MX2007003505A (es) Combinacion que comprende zd6474 e imatinib.
CY1111482T1 (el) Συνδυασμος azd2171 και πεμετρεξεδης
MX2007003506A (es) Terapia de combinacion de cancer que comprende azd2171 e imatinib.
NO20056170L (no) Kreftkombinasjonsterapi omfattende AZD2171 of ZD1839
NO20064755L (no) Kombinasjonsterapi
NO20056171L (no) Kombinasjonsterapi
NO20064754L (no) Kombinasjonsterapi
DE60308403D1 (de) Kombinationstherapie mit gemzitabin und zd6126

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1551409

Country of ref document: EP